Trial · NCT07165418
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
NCT07165418, Phase 3, Not yet recruiting, Peking University Cancer Hospital & Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI. Trials, record NCT07165418. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07165418
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
- NCT number
- NCT07165418
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 116 participants, estimated
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- Vorolanib Tablets+Everolimus, Sunitinib
- First posted
- 2025-09-10
- Last updated
- 2025-09-10
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival（PFS） | The time from study entry to the first disease progression (PD) or death .Estimate up to 2 years. | The time from study entry to the first disease progression (PD) or death from any cause, as assessed by the investigator. |
| Secondary | Overall Survival（OS） | The duration of treatment is determined from the start date to the date of death, or the last visit date serves.Estimate up to 3 years | The duration of treatment is determined from the start date to the date of death, regardless of the cause of death. For patients still alive at the time of final analysis, the last visit date serves as both the observation endpoint and the censoring date. |
| Secondary | Objective Response Rate（ORR） | From the start of receiving the treatment regimen in this study until the subject's disease progression and subsequent withdrawal from the study.Estimate up to 2 years | The percentage of subjects achieving a best response of complete remission (CR) or partial remission (PR) from the start of the study treatment regimen until disease progression or withdrawal from the study, relative to the total number of subjects in the analysis set. Assessed using RECIST 1.1 criteria. |
| Secondary | Disease Control Rate（DCR） | Estimate up to 2 years | The proportion of subjects achieving complete remission (CR), partial remission (PR), and stable disease (SD) among all subjects. |
| Secondary | Duration of Relief (DOR) | The time from the first assessment of tumor response as CR or PR (whichever occurs first) to the first assessment of PD or death from any cause (whichever occurs first).Estimate up to 2 years. | The time from the first assessment of tumor response as CR or PR (whichever occurs first) to the first assessment of PD or death from any cause (whichever occurs first). |
| Secondary | Adverse Events (AE) | about 2 years | Incidence and grade (including serious adverse events and immunization-related adverse events), as determined by NCI-CTCAE 5.0 criteria |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07165418
GET https://conductscience.org/api/trials/v1/NCT07165418/registered